CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models

BACKGROUND: Glioblastoma (GBM) is a devastating primary brain tumor with a highly immunosuppressive tumor microenvironment, and treatment with oncolytic viruses (OVs) has emerged as a promising strategy for these tumors. Our group constructed a new OV named Delta-24-ACT, which was based on the Delta...

Descripción completa

Detalles Bibliográficos
Autores principales: Puigdelloses, Montserrat, Garcia-Moure, Marc, Labiano, Sara, Laspidea, Virginia, Gonzalez-Huarriz, Marisol, Zalacain, Marta, Marrodan, Lucia, Martinez-Velez, Naiara, De la Nava, Daniel, Ausejo, Iker, Hervás-Stubbs, Sandra, Herrador, Guillermo, Chen, ZhiHong, Hambardzumyan, Dolores, Patino Garcia, Ana, Jiang, Hong, Gomez-Manzano, Candelaria, Fueyo, Juan, Gállego Pérez-Larraya, Jaime, Alonso, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291319/
https://www.ncbi.nlm.nih.gov/pubmed/34281988
http://dx.doi.org/10.1136/jitc-2021-002644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291319/
https://www.ncbi.nlm.nih.gov/pubmed/34281988
http://dx.doi.org/10.1136/jitc-2021-002644

Ejemplares similares